Spanish Red Biotech Pipeline

MSD

Favezelimab/Pembrolizumab/Lenvatinib

Type: Biodrugs/ Drugs
Therapeutic area: Cancer
Indication: MK-4280 as Monotherapy and in Combination with Pembrolizumab with or without Chemotherapy or Lenvatinib (E7080/MK-7902) in Subjects with Advanced Solid Tumor
Phase: 1Phase I in Spain